Valion Bio, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 09/30/25 | FY 06/30/25 | FY 12/31/24 | FY 12/31/23 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | — | $780,000 | $1.2M |
| Cost of revenue | — | — | — | $778,000 | $889,000 |
| Gross profit | — | — | — | $2,000 | $287,000 |
| Selling, general & administrative | $4.8M | — | — | $3.2M | — |
| Research and development | $3.1M | — | — | $1.3M | $1.7M |
| Operating expenses | $7.9M | — | — | $4.5M | $8.5M |
| Operating income | -$7.9M | — | — | -$4.5M | -$8.2M |
| Interest expense | $146,000 | — | — | $0 | — |
| Pretax income | — | — | — | — | -$8.2M |
| Income tax expense | $0 | — | — | $0 | — |
| Net income | -$8.9M | — | — | -$5.7M | -$8.2M |
| Balance Sheet | |||||
| Cash and equivalents | $12.6M | — | — | $2.0M | $3.4M |
| Current assets | $13.0M | — | — | $2.6M | $4.7M |
| Total assets | $31.6M | — | — | $2.8M | $5.2M |
| Current liabilities | $646,000 | — | — | $272,000 | $1.4M |
| Total liabilities | $7.4M | — | — | $272,000 | $1.6M |
| Stockholders' equity | $16.8M | $3.4M | $3.3M | $2.5M | $3.6M |
| Cash Flow Statement | |||||
| Cash from operations | -$7.0M | — | — | -$5.7M | -$8.5M |
| Depreciation and amortization | $5,000 | — | — | $3,000 | $8,000 |
| Stock-based compensation | $564,000 | — | — | $229,000 | $271,000 |
| Capital expenditure | $38,000 | — | — | $0 | $118,000 |
| Free cash flow | -$7.0M | — | — | -$5.7M | -$8.6M |
| Dividends paid | $0 | — | — | $0 | $0 |
| Impairments | — | — | — | $0 | $0 |
Shares outstanding 3.2M · Free float 16.3%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.